Research & Literature

Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.

Beuschlein F, Weigel J, Saeger W, et al.

The Journal of clinical endocrinology and metabolism 2015; (100(3)):841-9 doi:10.1210/jc.2014-3182.

Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry.

Petersenn S, Richter PA, Broemel T, et al.

European journal of endocrinology 2015; (172(4)):415-22 doi:10.1530/EJE-14-0916.

Risk of catecholaminergic crisis following glucocorticoid administration in patients with an adrenal mass: a literature review.

Barrett C, van Uum SH, Lenders JW

Clinical endocrinology 2015; (83(5)):622-8 doi:10.1111/cen.12813.

Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.

Margonis GA, Kim Y, Prescott JD, et al.

Annals of surgical oncology 2016; (23(1)):134-41 doi:10.1245/s10434-015-4803-x.

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.

Libé R, Borget I, Ronchi CL, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(10)):2119-25 doi:10.1093/annonc/mdv329.

Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases.

Duregon E, Volante M, Bollito E, et al.

Human pathology 2015; (46(12)):1799-807.

Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.

Bornstein SR, Allolio B, Arlt W, et al.

The Journal of clinical endocrinology and metabolism 2016; (101(2)):364-89 doi:10.1210/jc.2015-1710.

Comparison of the methods for measuring the Ki-67 labeling index in adrenocortical carcinoma: manual versus digital image analysis.

Yamazaki Y, Nakamura Y, Shibahara Y, et al.

Human pathology 2016; (53()):41-50.

European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.

Plouin PF, Amar L, Dekkers OM, et al.

European journal of endocrinology 2016; (174(5)):G1-G10 doi:10.1530/EJE-16-0033.

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors.

Fassnacht M, Arlt W, Bancos I, et al.

European journal of endocrinology 2016; (175(2)):G1-G34 doi:10.1530/EJE-16-0467.

Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients.

Lee CW, Salem AI, Schneider DF, et al.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2017; (21(2)):352-362 doi:10.1007/s11605-016-3262-4.

Adrenal crisis secondary to bilateral adrenal haemorrhage after hemicolectomy.

Logaraj A, Tsang VH, Kabir S, Ip JC

Endocrinology, diabetes & metabolism case reports 2016; (2016()).

Refractory hypoglycemia in a patient with functional adrenal cortical carcinoma.

Marchetti KR, Pereira MA, Lichtenstein A, Paiva EF

Endocrinology, diabetes & metabolism case reports 2016; (2016()).

Preoperative alpha-blockade in phaeochromocytoma and paraganglioma: is it always necessary?

Isaacs M, Lee P

Clinical endocrinology 2017; (86(3)):309-314 doi:10.1111/cen.13284.

DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.

Jouinot A, Assie G, Libe R, et al.

The Journal of clinical endocrinology and metabolism 2017; (102(3)):923-932 doi:10.1210/jc.2016-3205.

Surgical Management of Adrenocortical Carcinoma: Impact of Laparoscopic Approach, Lymphadenectomy, and Surgical Volume on Outcomes-A Systematic Review and Meta-analysis of the Current Literature.

Langenhuijsen J, Birtle A, Klatte T, et al.

European urology focus 2016; (1(3)):241-250 doi:10.1016/j.euf.2015.12.001.

Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.

Reimondo G, Puglisi S, Zaggia B, et al.

European journal of endocrinology 2017; (177(4)):361-367 doi:10.1530/EJE-17-0452.

Management of an acute catecholamine-induced cardiomyopathy and circulatory collapse: a multidisciplinary approach.

Casey RT, Challis BG, Pitfield D, et al.

Endocrinology, diabetes & metabolism case reports 2017; (2017()) doi:10.1530/EDM-17-0122.

Challenges in surgical pathology of adrenocortical tumours.

Erickson LA

Histopathology 2018; (72(1)):82-96 doi:10.1111/his.13255.

Radiological Surveillance Screening in Asymptomatic Succinate Dehydrogenase Mutation Carriers.

Tufton N, Sahdev A, Akker SA

Journal of the Endocrine Society 2017; (1(7)):897-907 doi:10.1210/js.2017-00230.

SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook.

Reznik Y, Barat P, Bertherat J, et al.

Annales d'endocrinologie 2018; (79(1)):1-22 doi:10.1016/j.ando.2017.12.001.

A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma: ASES score.

Cho YY, Kwak MK, Lee SE, et al.

Surgery 2018; (164(3)):511-517 doi:10.1016/j.surg.2018.05.001.

Adrenocortical carcinoma (ACC): When and why should we consider germline testing?

Petr EJ, Else T

Presse medicale (Paris, France : 1983) 2018; (47(7-8 Pt 2)):e119-e125 doi:10.1016/j.lpm.2018.07.004.

Risk Stratification on Pheochromocytoma and Paraganglioma from Laboratory and Clinical Medicine.

Kimura N, Takekoshi K, Naruse M

Journal of clinical medicine 2018; (7(9)) doi:10.3390/jcm7090242.

Primary adrenal insufficiency due to bilateral infiltrative disease.

Herndon J, Nadeau AM, Davidge-Pitts CJ, et al.

Endocrine 2018; (62(3)):721-728 doi:10.1007/s12020-018-1737-7.

Evaluation, Staging, and Surgical Management for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group.

Dickson PV, Kim L, Yen TWF, et al.

Annals of surgical oncology 2018; (25(12)):3460-3468 doi:10.1245/s10434-018-6749-2.

Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma.

Pryma DA, Chin BB, Noto RB, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019; (60(5)):623-630 doi:10.2967/jnumed.118.217463.

European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

Fassnacht M, Dekkers OM, Else T, et al.

European journal of endocrinology 2018; (179(4)):G1-G46 doi:10.1530/EJE-18-0608.

Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis.

Vanbrabant T, Fassnacht M, Assie G, Dekkers OM

European journal of endocrinology 2018; (179(6)):429-436.

Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma.

Muth A, Crona J, Gimm O, et al.

Journal of internal medicine 2019; (285(2)):187-204 doi:10.1111/joim.12869.

Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.

Buffet A, Ben Aim L, Leboulleux S, et al.

The Journal of clinical endocrinology and metabolism 2019; (104(4)):1109-1118 doi:10.1210/jc.2018-02411.

Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma.

Mohan DR, Lerario AM, Else T, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(11)):3276-3288 doi:10.1158/1078-0432.CCR-18-2693.

Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature.

Łebek-Szatańska A, Nowak KM, Zgliczyński W, et al.

Therapeutic advances in endocrinology and metabolism 2019; (10()):2042018819825541 doi:10.1177/2042018819825541.

Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.

Crona J, Lamarca A, Ghosal S, et al.

Endocrine-related cancer 2019; (26(5)):539-550.

Adrenal crisis: prevention and management in adult patients.

Dineen R, Thompson CJ, Sherlock M

Therapeutic advances in endocrinology and metabolism 2019; (10()):2042018819848218 doi:10.1177/2042018819848218.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taïeb D, Hicks RJ, Hindié E, et al.

European journal of nuclear medicine and molecular imaging 2019; (46(10)):2112-2137 doi:10.1007/s00259-019-04398-1.

Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.

Assié G, Jouinot A, Fassnacht M, et al.

JAMA oncology 2019; (5(10)):1440-1447 doi:10.1001/jamaoncol.2019.1558.

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment.

Puglisi S, Calabrese A, Basile V, et al.

Journal of clinical medicine 2019; (8(11)) doi:10.3390/jcm8111850.

Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.

Buitenwerf E, Osinga TE, Timmers HJLM, et al.

The Journal of clinical endocrinology and metabolism 2020; (105(7)) doi:10.1210/clinem/dgz188.

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.

Poirier J, Gagnon N, Terzolo M, et al.

Cancers 2020; (12(3)) doi:10.3390/cancers12030639.

New perspectives for mitotane treatment of adrenocortical carcinoma.

Puglisi S, Calabrese A, Basile V, et al.

Best practice & research. Clinical endocrinology & metabolism 2020; (34(3)):101415 doi:10.1016/j.beem.2020.101415.

Surgery for adrenocortical carcinoma: When and how?

Sinclair TJ, Gillis A, Alobuia WM, et al.

Best practice & research. Clinical endocrinology & metabolism 2020; (34(3)):101408 doi:10.1016/j.beem.2020.101408.

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience.

Laganà M, Grisanti S, Cosentini D, et al.

Cancers 2020; (12(4)) doi:10.3390/cancers12040941.

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of adrenal insufficiency.

Arlt W, Baldeweg SE, Pearce SHS, Simpson HL

European journal of endocrinology 2020; (183(1)):G25-G32.

Past, Present and Future of Epigenetics in Adrenocortical Carcinoma.

Ettaieb M, Kerkhofs T, van Engeland M, Haak H

Cancers 2020; (12(5)) doi:10.3390/cancers12051218.

The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know.

Cass ND, Schopper MA, Lubin JA, et al.

The Annals of otology, rhinology, and laryngology 2020; (129(11)):1135-1143 doi:10.1177/0003489420931540.

Management of adrenocortical carcinoma in Western Australia: a perspective over 14 years.

Leong D, Nyantoro M, Shedzad H, et al.

ANZ journal of surgery 2021; (91(1-2)):62-67 doi:10.1111/ans.16111.

Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study.

Bancos I, Taylor AE, Chortis V, et al.

The lancet. Diabetes & endocrinology 2020; (8(9)):773-781 doi:10.1016/S2213-8587(20)30218-7.

Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas.

Y-Hassan S, Falhammar H

Journal of clinical medicine 2020; (9(8)) doi:10.3390/jcm9082435.

Venous thromboembolism in patients with adrenocortical carcinoma after surgery.

Durmuşoğlu J, Timmers HJLM, van Houten P, et al.

Endocrine connections 2020; (9(9)):874-881.

Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.

Vikner ME, Krogh J, Daugaard G, Andreassen M

Clinical endocrinology 2021; (94(2)):141-149 doi:10.1111/cen.14345.

131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma.

Jungels C, Karfis I

Current opinion in oncology 2021; (33(1)):33-39 doi:10.1097/CCO.0000000000000691.

Preoperative Management of Pheochromocytoma and Paraganglioma.

Fang F, Ding L, He Q, Liu M

Frontiers in endocrinology 2020; (11()):586795 doi:10.3389/fendo.2020.586795.

Pheochromocytoma and Paraganglioma: From Treatment to Follow-up.

Aygun N, Uludag M

Sisli Etfal Hastanesi tip bulteni 2020; (54(4)):391-398 doi:10.14744/SEMB.2020.58998.

Metastatic Pheochromocytomas and Abdominal Paragangliomas.

Granberg D, Juhlin CC, Falhammar H

The Journal of clinical endocrinology and metabolism 2021; (106(5)):e1937-e1952 doi:10.1210/clinem/dgaa982.

The Role of Biomarkers in Adrenocortical Carcinoma: A Review of Current Evidence and Future Perspectives.

Mizdrak M, Tičinović Kurir T, Božić J

Biomedicines 2021; (9(2)) doi:10.3390/biomedicines9020174.

High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma.

Jha A, Taïeb D, Carrasquillo JA, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2021; (27(11)):2989-2995 doi:10.1158/1078-0432.CCR-20-3703.

Helping young children understand inherited cancer predisposition syndromes using bibliotherapy.

Schlub GM, Crook A, Barlow-Stewart K, et al.

Journal of genetic counseling 2021; (30(4)):1119-1132 doi:10.1002/jgc4.1396.

American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.

Kiseljak-Vassiliades K, Bancos I, Hamrahian A, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(11)):1366-1383 doi:10.4158/DSCR-2020-0567.

Non-functioning adrenocortical carcinoma.

Lenh BV, Duc NM, Tra My TT, et al.

Radiology case reports 2021; (16(6)):1329-1334 doi:10.1016/j.radcr.2021.03.006.

Glucocorticoid induced adrenal insufficiency.

Prete A, Bancos I

BMJ (Clinical research ed.) 2021; (374()):n1380 doi:10.1136/bmj.n1380.

[Adrenal imaging: anatomy and pathology (literature review)].

Korb TA, Chernina VY, Blokhin IA, et al.

Problemy endokrinologii 2021; (67(3)):26-36 doi:10.14341/probl12752.

Giant androgen-producing adrenocortical carcinoma with atrial flutter: A case report and review of the literature.

Costache MF, Arhirii RE, Mogos SJ, et al.

World journal of clinical cases 2021; (9(20)):5575-5587 doi:10.12998/wjcc.v9.i20.5575.

Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy.

Altieri B, Lalli E, Faggiano A

Minerva endocrinology 2022; (47(2)):203-214 doi:10.23736/S2724-6507.21.03601-0.

Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study.

Davidoff DF, Benn DE, Field M, et al.

The Journal of clinical endocrinology and metabolism 2022; (107(5)):e1907-e1916 doi:10.1210/clinem/dgac019.

The Effect of Surgeon Expertise on the Outcome of Patients with Adrenocortical Carcinoma.

Barac Nekic A, Knezevic N, Zibar Tomsic K, et al.

Journal of personalized medicine 2022; (12(1)) doi:10.3390/jpm12010100.

Perioperative Management of Pheochromocytomas and Sympathetic Paragangliomas.

Fagundes GFC, Almeida MQ

Journal of the Endocrine Society 2022; (6(2)):bvac004 doi:10.1210/jendso/bvac004.

[Emergency card, emergency medication, and information leaflet for the prevention and treatment of adrenal crisis (Addison crisis): an Austrian consensus document].

Pilz S, Krebs M, Bonfig W, et al.

Journal fur klinische Endokrinologie und Stoffwechsel 2022; (15(1)):5-27 doi:10.1007/s41969-022-00155-2.

Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Mete O, Erickson LA, Juhlin CC, et al.

Endocrine pathology 2022; (33(1)):155-196 doi:10.1007/s12022-022-09710-8.

Preoperative blood pressure targets and effect on hemodynamics in pheochromocytoma and paraganglioma.

Ugleholdt R, Rasmussen ÅK, Haderslev PAH, et al.

Endocrine connections 2022; (11(5)).

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity.

Steenaard RV, Rutjens M, Ettaieb MHT, et al.

Discover oncology 2022; (13(1)):25 doi:10.1007/s12672-022-00486-1.

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.

Turla A, Laganà M, Grisanti S, et al.

Endocrine 2022; (77(3)):438-443 doi:10.1007/s12020-022-03075-y.

ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.

Terzolo M, Fassnacht M

European journal of endocrinology 2022; (187(3)):R27-R40 doi:10.1530/EJE-22-0260.

[Are there still indications for open adrenalectomy?]

Holzer K, Bartsch DK

Chirurgie (Heidelberg, Germany) 2022; (93(9)):856-860 doi:10.1007/s00104-022-01678-9.

Clinical characteristics and outcomes of pheochromocytoma crisis: a literature review of 200 cases.

Ando Y, Ono Y, Sano A, et al.

Journal of endocrinological investigation 2022; (45(12)):2313-2328 doi:10.1007/s40618-022-01868-6.

American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.

Yip L, Duh QY, Wachtel H, et al.

JAMA surgery 2022; (157(10)):870-877 doi:10.1001/jamasurg.2022.3544.

The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation.

Tizianel I, Caccese M, Torresan F, et al.

Cancers 2022; (14(16)) doi:10.3390/cancers14163904.

Diagnosis and Management of Adrenal Insufficiency and Adrenal Crisis in the Emergency Department.

Lentz S, Collier KC, Willis G, Long B

The Journal of emergency medicine 2022; (63(2)):212-220 doi:10.1016/j.jemermed.2022.06.005.

Open Versus Laparoscopic Surgery in the Management of Adrenocortical Carcinoma: A Systematic Review and Meta-analysis.

Nakanishi H, Miangul S, Wang R, et al.

Annals of surgical oncology 2023; (30(2)):994-1005 doi:10.1245/s10434-022-12711-w.

A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors.

Padua TC, Marandino L, Raggi D, et al.

Clinical genitourinary cancer 2023; (21(1)):1-7 doi:10.1016/j.clgc.2022.10.011.

Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.

Poirier J, Godemel S, Mourot A, et al.

The Journal of clinical endocrinology and metabolism 2023; (108(9)):2336-2342 doi:10.1210/clinem/dgad115.

Genetic Testing for Adrenal Tumors-What the Contemporary Surgeon Should Know.

Bates MF, Sorensen MJ

Surgical oncology clinics of North America 2023; (32(2)):303-313 doi:10.1016/j.soc.2022.10.007.

Biochemical Assessment of Pheochromocytoma and Paraganglioma.

Eisenhofer G, Pamporaki C, Lenders JWM

Endocrine reviews 2023; (44(5)):862-909 doi:10.1210/endrev/bnad011.

[Guidelines of the French National ENDOCAN-COMETE, Association of Endocrine Surgery, Society of Urology for the management of adrenocortical carcinoma].

Libé R, Haissaguerre M, Renaudin K, et al.

Bulletin du cancer 2023; (110(6)):707-730 doi:10.1016/j.bulcan.2023.03.015.

European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors.

Fassnacht M, Tsagarakis S, Terzolo M, et al.

European journal of endocrinology 2023; (189(1)):G1-G42 doi:10.1093/ejendo/lvad066.

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.

Mormando M, Galiè E, Bianchini M, et al.

Frontiers in oncology 2023; (13()):1222002 doi:10.3389/fonc.2023.1222002.

Dual Aldosterone- and Cortisol-Secreting Adrenal Cortical Carcinoma: Pre- and Perioperative Evaluation and Management.

Rosenberg R, Raeburn CD, Clay MR, Wierman ME

JCEM case reports 2023; (1(4)):luad073 doi:10.1210/jcemcr/luad073.

Catecholamine-induced hypertensive crises: current insights and management.

Nazari MA, Hasan R, Haigney M, et al.

The lancet. Diabetes & endocrinology 2023; (11(12)):942-954 doi:10.1016/S2213-8587(23)00256-5.

Primary perioperative haemodynamic effects of ß-receptor blockade in patients with catecholamine-secreting tumours.

Groeben H, Nottebaum BJ, Feldheiser A, et al.

BJA open 2023; (8()):100240 doi:10.1016/j.bjao.2023.100240.

Current prospects of hereditary adrenal tumors: towards better clinical management.

Ohmoto A, Hayashi N, Takahashi S, Ueki A

Hereditary cancer in clinical practice 2024; (22(1)):4 doi:10.1186/s13053-024-00276-6.

International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.

Riedmeier M, Antonini SRR, Brandalise S, et al.

European journal of endocrinology 2024; (190(4)):G15-G24 doi:10.1093/ejendo/lvae038.

Li-Fraumeni Syndrome With Six Primary Tumors-Case Report.

Stojiljković D, Cvetković A, Jokić A, et al.

Case reports in oncological medicine 2024; (2024()):6699698 doi:10.1155/2024/6699698.

[Adrenal tumors: current standards in clinical management].

Fuß CT, Megerle F, Fassnacht M

Innere Medizin (Heidelberg, Germany) 2024; (65(7)):632-641 doi:10.1007/s00108-024-01727-x.

Cardiogenic shock in phaeochromocytoma multisystem crisis: a case report.

Go YY, Ng AJT, Balakrishnan ID, et al.

European heart journal. Case reports 2024; (8(9)):ytae463 doi:10.1093/ehjcr/ytae463.

Progress in surgical approaches and outcomes of patients with pheochromocytoma and paraganglioma.

Friedman LR, Ramamoorthy B, Nilubol N

Best practice & research. Clinical endocrinology & metabolism 2025; (39(1)):101954 doi:10.1016/j.beem.2024.101954.

Survival impact of treatment utilization and margin status after resection of adrenocortical carcinoma.

Memeh K, Abou Azar S, Afolaranmi O, Vaghaiwalla TM

American journal of surgery 2025; (239()):115999 doi:10.1016/j.amjsurg.2024.115999.

The impact of adrenocortical carcinoma hormone secreting status as a predictor of poor survival: a systematic review and meta-analysis.

Nastos C, Papaconstantinou D, Paspala A, et al.

Langenbeck's archives of surgery 2024; (409(1)):316 doi:10.1007/s00423-024-03507-5.

Bilateral adrenal hemorrhage in a postpartum woman with multiple thromboemboli: A case report.

Jiang AYN, Abasszade JH, Abrahams T, et al.

Journal of medical case reports 2024; (18(1)):518 doi:10.1186/s13256-024-04834-3.

Treatment and Prevention of Adrenal Crisis and Family Education

Çamtosun E, Sangün Ö

Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):80-92 doi:10.4274/jcrpe.galenos.2024.2024-6-12-S.

Adrenocortical Carcinoma With 2 Distinct Syndromes From Secretion of Insulin-Like Growth Factor 2 and Steroid Hormones.

Lonergan EM, Tan LYJ, O'Sullivan A, et al.

JCEM case reports 2025; (3(6)):luaf078 doi:10.1210/jcemcr/luaf078.

Adrenal Insufficiency in Adults: A Review.

Vaidya A, Findling J, Bancos I

JAMA 2025; (334(8)):714-725 doi:10.1001/jama.2025.5485.

Report of a rare case of childhood adrenocortical carcinoma and literature review.

Wu Z, Qiu L, Zhang M, Chen G

Urology case reports 2025; (61()):103113 doi:10.1016/j.eucr.2025.103113.

Management of cushing's syndrome in patients with adrenocortical cancer: state of the art and future perspectives.

Guarnotta V, Stigliano A, Terzolo M, Arnaldi G

Reviews in endocrine & metabolic disorders 2025; (26(6)):1023-1035 doi:10.1007/s11154-025-09989-y.

Phase II Study of 177Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.

Lin FI, Del Rivero J, Carrasquillo JA, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(28)):3102-3112 doi:10.1200/JCO-25-00791.

Diagnosis and grading of adrenal cortical carcinoma.

Vocino Trucco G, Duregon E, Papotti M, Volante M

Virchows Archiv : an international journal of pathology 2026; (488(1)):193-210 doi:10.1007/s00428-025-04278-0.

Genomic Sequencing in Oncocytic Adrenal Carcinoma May Provide Insights into Disease Progression and Treatment Options.

Han HJ, Moore A, Numbere N, et al.

JCEM case reports 2025; (3(11)):luaf227 doi:10.1210/jcemcr/luaf227.

Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.

Somoto T, Utsumi T, Ikeda R, et al.

Current oncology (Toronto, Ont.) 2025; (32(12)) doi:10.3390/curroncol32120698.

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Greenberg SE, Skefos CM, Vagher J

Endocrinology and metabolism clinics of North America 2026; (55(2)):299-315 doi:10.1016/j.ecl.2026.01.002.

Hormonal functional status and prognostic stratification in adrenocortical carcinoma: a single-center retrospective cohort study.

Guerrero-Pérez F, Tarruella Planas M, Weilg Espejo C, et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026; doi:10.1007/s12094-026-04409-2.

Real-world safety profile of mitotane in adrenocortical carcinoma: a retrospective cross-sectional study integrating pharmacovigilance and interpretable machine learning.

Wang J, Yang Y, Xu K, et al.

Frontiers in endocrinology 2026; (17()):1862262 doi:10.3389/fendo.2026.1862262.

Retroperitoneal paraganglioma mimicking a solid pseudopapillary neoplasm of the pancreatic tail and confirmed by percutaneous biopsy: a case report.

Song J, Sun W, Ren Y, et al.

Frontiers in oncology 2026; (16()):1838923 doi:10.3389/fonc.2026.1838923.